GENFIT (GNFT), a late-stage biopharmaceutical company developing drugs for rare and life-threatening liver diseases, has a regulatory catalyst to watch this quarter.
The company's investigational drug Elafibranor, proposed for the treatment of primary biliary cholangitis, is under priority review by the FDA, with a decision due on June 10, 2024.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com